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The term autoinflammation was initially introduced to
denote a group of diseases that lacked the usual features
of autoimmunity (high-titer autoantibodies and antigen-
specific T cells), and were subsequently recognized as
disorders of the innate immune system. Patients with
autoinflammatory disorders present with chronic and
recurrent bouts of systemic inflammation that are medi-
ated by the cells of the innate immune system such as
neutrophils and macrophages. The concept of autoin-
flammation started with hereditary recurrent fevers, but
has grown substantially to include both monogenic and
polygenic diseases. Hereditary recurrent fevers are the
prototypic monogenic disorders, whereas Behçet disease,
Crohn disease, gout, spondyloarthropathies, type-2
diabetes are all considered complex autoinflammatory
diseases. The monogenic autoinflammatory diseases are
inherited in an autosomal-recessive or autosomal-
dominant fashion, and many of disease-causing mutations
are found in genes that regulate the IL-1 signaling path-
way. More recently, new pathways such as the IL-36,
immunoproteasome, HOIL-1 deficiency, and phos-
pholipase Cg2 pathways have been identified in the
pathogenesis of autoinflammation. Some of these new
autoinflammatory diseases and relevant pathways will be
discussed at the meeting. Despite major advances, a sub-
stantial number of patients have no mutations in the
known autoinflammatory genes. The present challenge is
how to find the as-yet undiscovered genes, considering
that most cases are sporadic or occur in small families that
are not suit-able for linkage analysis. New approaches and
tools such as next-generation sequencing are the most
likely methods to be successful. Such research might
require collabora-tive studies in order to increase the
number of patients presenting with a rare phenotype.
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